The cytokines remaining in patients on ibrutinib that are blocked by ruxolitinib to allow CLL cells to acquire a phenotype associated with cell cycle progression and NFκB activation (Figure 3) are presently unknown. The gene discussed is NFKB1; the disease is B-cell chronic lymphocytic leukemia.